Abstract
Background
Enterococcus faecalis is a common cause of healthcare-associated infections. Its resistance to linezolid, the antibiotic of last resort for vancomycin-resistant enterococci, has become a growing threat in healthcare settings.
Methods
We analyzed the data of E. faecalis isolates from 26 medical institutions between 2018 and 2020 and performed univariate and multivariate logistic regression analyses to determine the independent predictors for linezolid-resistant E. faecalis (LREFs). Then, we used the artificial neural network (ANN) and logistic regression (LR) to build a prediction model for linezolid resistance and performed a performance evaluation and comparison.
Results
Of 12,089 E. faecalis strains, 755 (6.25%) were resistant to linezolid. Among vancomycin-resistant E. faecalis, the linezolid-resistant rate was 24.44%, higher than that of vancomycin-susceptible E. faecalis (p < 0.0001). Univariate and multivariate regression analyses showed that gender, age, specimen type, length of stay before culture, season, region, GDP (gross domestic product), number of beds, and hospital level were predictors of linezolid resistance. Both the ANN and LR models constructed in the study performed well in predicting linezolid resistance in E. faecalis, with AUCs of 0.754 and 0.741 in the validation set, respectively. However, synthetic minority oversampling technique (SMOTE) did not improve the prediction ability of the models.
Conclusion
E. faecalis linezolid-resistant rates varied by specimen site, geographic region, GDP level, facility level, and the number of beds. At the same time, community-acquired E. faecalis with linezolid resistance should be monitored closely. We can use the prediction model to guide clinical medication and take timely prevention and control measures.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
E. faecalis is a Gram-positive, facultatively anaerobic, catalase-negative bacteria that normally lives in the intestines of healthy humans [1] and also widely distributed in nature. However, it can survive under harsh conditions [2] due to its resilient and versatile features, especially its intrinsic resistance to various antimicrobials and acquisition of resistance traits [3], which may cause serious infections in hospitals and difficult to treat. At 2020, it had become the third most common gram-positive bacteria and the fifth most common pathogen in healthcare-associated infections (HAI) worldwide from CHINET surveillance [4, 5].
Linezolid, as the last-line drug for vancomycin-resistant E. faecalis, has been frequently used in the clinical treatment of various serious infections such as pneumonia, meningitis, or skin infections, and also used for treating difficult infections and multi-drug resistant tuberculosis [6, 7]. Although the incidence of linezolid-resistant E. faecalis in humans is still very low, the emergence of linezolid-transferable resistance genes cfr, cfr(B), cfr(C), poxtA, and optrA in recent years [8,9,10,11] has raised concerns about the impact of E. faecalis on linezolid drug resistance. Linezolid resistance can also be caused by mutations in the 23S rRNA gene, and all of the above genes are increasingly observed in food-producing animals, food of animal origin, and humans[12]. Some studies have reported high detection of linezolid-insensitive E. faecalis, even be as high as 18% in food-producing animals [13, 14]. Due to the abuse of antimicrobial drugs and poor prevention and control, the resistance rate of E. faecalis to linezolid may gradually increase. Therefore, we need to monitor and predict the epidemiology of linezolid- resistant E. faecalis. This study will build a predictive model for linezolid resistance, which can guide clinicians on how to use antibiotics rationally and empirically and decision makers on how to formulate prevention and control measures timely and effective.
Methods
We used big data from the Hospital Infection Prevention and Control Center System (NICC), a real-time monitoring system that receives healthcare-association infection data from secondary and above medical institutions across the province, to conduct a retrospective observational study of E. faecalis. For avoiding systematic bias due to changes in hospital participation over time, we included data from 26 medical institutions which uploading relatively complete data for more than 36 months from 2018 to 2021.
Selection of E. faecalis isolates
We extracted relevant data on E. faecalis reported by 26 medical institutions above from the system from 2018 to 2021. We selected only the first E. faecalis isolate from each inpatient and excluded duplicate isolates. We also excluded isolates that did not have linezolid susceptibility testing or had missing information on the factors. We defined linezolid resistant E. faecalis (LREfs) as those that were reported as linezolid-intermediate or linezolid-resistant by the medical institutions. We defined linezolid-susceptible E. faecalis (LSEfs) as those that were reported as linezolid-sensitive. Sensitivity judgments for other antibiotics also follow the above principles. The Clinical and Laboratory Standards Institute (CLSI) M100 standard is followed by the microbiological labs in the hospitals where we collected our data.
Factors
We collected possible risk factors and categorized them. The age of patients was divided into four age groups (0–18, 19–45, 46–65, and 66-year-old). Patients were divided into female and male. The sources of isolates are divided into north, west, south, and east regions and are divided into two categories: 0–P50 and P51 or above according to the GDP of the source area. Isolate acquisition time is divided into spring, summer, autumn, and winter, according to the season, and divided into 5 categories (0–2, 3–7, 8–14, 15–28, and 29 days) according to the number of days of hospitalization when the pathogen was detected. The source of the isolate is divided into respiratory, urinary, cerebrospinal fluid, secretion, blood, drain fluid, and others. The hospital is divided into secondary-level hospital and tertiary-level hospital according to the type of hospital and divided into five categories according to the number of beds (0–500, 501–1000, 1001–1500, 1501–2000, and 2001 beds). The source department of isolates is divided into the intensive care unit and non-intensive care unit.
Statistical analysis
We used SAS software (version 9.4, SAS Institute, Cary, NC, USA) or R software (version 4.2.1, R Foundation, Vienna, Austria) for statistical analyses. The primary outcome was the proportion of E. faecalis isolates that were not susceptible to linezolid (%). We reported continuous variables as means or medians, and categorical variables as frequencies or proportions. We used the Chi-squared test to compare the proportions of LREfs by different variables.
SMOTE
Synthetic minority oversampling technique (SMOTE) is a common oversampling method that creates synthetic samples based on the features of the minority class instances and their nearest neighbors. SMOTE increases the number of minority class without affecting the number of majority class [15]. In this study, we used SMOTE to balance the training set so that the ratio of positive samples (LSEfs) to negative samples (LREfs) was close to 1:1.
Predictive model construction
We randomly split the data set into a training set (70%) and an independent validation set (30%). We used univariate and multivariate logistic regression analyses for variable screening only in the training set. Factors that were statistically significant (a p-value less than 0.05 was considered significant) in the univariate logistic regression analysis were input variables in the artificial neural network (ANN) and multivariate analyses. Then, we used stepwise logistic regression for multivariate analysis to determine independent predictors. Both the ANN and logistic regression (LR) models were constructed on the same training set (with or without SMOTE) and tested on the same validation set.
We used RSNNS packages for R for ANN algorithms and the results of the multivariate analysis to build up the LR model. The dependent variable was LREfs rate. For internal validation, we used bootstrapping method. We used Youden index to determine accuracy, sensitivity, and specificity from the optimal threshold. And we measured accuracy, sensitivity, specificity, receiver operating characteristic (ROC) curve, area under the ROC curve (AUROC), calibration curves, leave-one-out cross validation, and decision curve analysis (DCA) on validation set to evaluate model performance [16]. The difference in AUROC values between the two models was compared with the method described by DeLong et al.
Results
We collected 364,886 isolates from clinical specimens of inpatients in 26 medical institutions from 2018 to 2021. Of these, 13,556(3.72%) were E. faecalis. 12,089 (89.18%) isolates of E. faecalis were tested to linezolid. A total of 755 isolates of LREfs were detected, with a resistant rate of 6.25%.
Drug susceptibility of E. faecalis
Among vancomycin-resistant E. faecalis, the linezolid resistance rate was 24.44%, which was higher than that of vancomycin-susceptible E. faecalis (p < 0.001). In addition, among E. faecalis resistant to penicillin, quinolones, tigecycline, tetracycline, or erythromycin, the rate of resistance to linezolid was also higher than that of sensitive strains, with statistical significance (p < 0.05) (shown in Fig. 1).
Correlative analysis of clinical data of LREfs
Basic characteristics of predictive factors related to LREfs
The 755 specimens of LREfs were mainly from people older than 46 (median age 59), with a male/female ratio of 1.23. There is no significant difference in distribution. Most of these specimens came from hospitals in the eastern region, tertiary hospitals, or hospitals with beds between 1501 and 2000. The specimens of LREfs obtained from non-ICU inpatients were the most, up to 88.48%. The number of samples of LREfs detected within 2 days after admission accounted for 49.27%. The number of specimens in spring, summer, and autumn was not much different, and the number of LREfs detected in winter was relatively small. The specimens were mainly from the respiratory system (49.27%), followed by urine (44.37%) and secretion (28.48%). The baseline characteristics of E. faecalis and LREfs are shown in supplemental Table A1.
Univariate and multivariate analyses of predictive factors for LREfs
Male and GDP > P50 were independent predictors (risk factors) of E. faecalis resistant to linezolid, while tertiary hospitals and winter were independent protective variables, according to univariate and multivariate regression analysis. Additionally, compared to E. faecalis isolates from respiratory specimens, E. faecalis isolates from drainage fluid, blood, and urine were less likely to be linezolid resistant. In comparison to hospitals with more than 2000 beds, those with fewer than 500 beds, 501–1000 beds, and 1501–2000 beds were more likely to find LREf isolates. The rate of LREf isolates in the northern region was lower than in the eastern region (showed in Fig. 2).
Changes in detection rate of LREfs with days of hospitalization in different GDP regions
Within 2 days of hospitalization, the resistant rate of E. faecalis from low-GDP regions was 3.54%, which was comparable to the rate observed after 2 days of hospitalization (3.36%). However, the rate of LREfs within 2 days in high-GDP areas was statistically higher than that after 2 days (9.56% vs. 7.35%; p < 0.001) (showed in Fig. 3).
A predictive model for LREfs
In the ANN prediction model, an input layer consisting of 23 neurons (including the 23 variables found in the univariable regression analysis) was parsed. The number of neurons in the hidden layer was determined to be 18 (showed in Fig. 2). And the LR prediction model was constructed by utilizing the independent predictors discovered in a multivariable investigation. In the training set, the AUC of ANN was greater than that of LR, and the difference was statistically significant (0.763 vs. 0.745, p < 0.001). But the predictive performance of the two models was comparable when predicted on the validation set. Additionally, after the training set was processed using the SMOTE, the predictive performance of the ANN and LR prediction models in the training set both not improved but decreased in the validation set (showed in Fig. 4). The calibration plot shows good predictive accuracy between the actual probability and predicted probability (showed in supplementary Figure A2). For the LR model, we use leave-one-out cross-validation to verify the generalization ability, and get AUC = 0.7311, additionally we evaluated the model’ clinical utility with DCA method, and the results showed that when the probability of LREFs is between 0 and 21%, the prediction model has good clinical utility (showed in Fig. 5). And the prediction performance of ANN and LR based on the optimal feature subset is compared through the sensitivity, specificity, accuracy, precision, F1 value, and AUC that are shown in Table 1.
Discussion
In the analysis of the drug susceptibility results of E. faecalis, bacteria that were resistant to vancomycin, penicillin, quinolones, tigecycline, tetracycline, and erythromycin seem to be more likely to be resistant to linezolid. Several studies have demonstrated that certain resistance genes associated with linezolid resistance, such as cfr and optrA, can confer resistance to multiple antibacterial agents simultaneously. Furthermore, the presence of IS256-like sequences may obscure additional resistance genes. Therefore, further research is necessary to elucidate the relationship between these antibiotic resistances [17, 18]. The probability of linezolid insensitivity in patients with the aforementioned antimicrobial drug resistance, however, may be increased by risk factors such immunocompromised individuals, the administration of numerous antibiotics, a prolonged hospital stay, and ICU admission[19]. On the other hand, they are increasingly resistant not only to antibiotics but also disinfectants which is complicating infection control recommendations [20, 21]. We must also mention that none of the E. faecalis from the 26 medical institutions in this study were tested for daptomycin susceptibility, which limits its use for E. faecalis infections and increases the options for linezolid and resistance to linezolid [22,23,24,25].
Our study also found that LREfs in high-income areas are higher than those in low-income areas, which is contrary to other studies [26, 27]. This may be due to more antimicrobial use and environmental contamination selecting for bacterial resistance in high-income areas. Additionally, LREfs from the community was also high in this study, specifically in high-income areas, and LREf intestinal tract colonization as a reservoir of LREfs acquired through the community may be asymptomatic but may occur infection in hospitals [28]. Sometimes LREfs carrying silent cfr and/or optrA from the community may be hard to detect in clinical setting [29], but may cause nosocomial outbreaks of LREfs infections [30, 31], endangering patients’ lives.
According to our multifactor analysis, we included eight variables to construct predictive models for LREfs using ANN and LR. The ANN model performed better on the training set, but both models performed similarly on the validation set with good predictive performance and robustness. The DCA curve of the LR model showed a better net benefit when the threshold probability was between 0 and 21%. We also used SMOTE technology to balance the data and improve the performance of the model in the validation set. After SMOTE processing, various performance indicators of the ANN model on the training set improved significantly. However, performance indicators on the validation set decreased instead. The SMOTE technique may cause overfitting and fail to generalize to new and unseen data. The prediction performance of the LR model following SMOTE treatment also did not improve.
We believe that our model can help clinical doctors to choose drugs reasonably after being applied to clinical practice and take effective prevention and control measures in a timely manner for high-risk populations who are insensitive to metronidazole, thereby reducing the burden of metronidazole resistance on patients and medical treatment. We also provided a nomogram diagram (showed in Fig. 6) for real-world use. This model’s advantages include ease of use and affordability, which can promote its use and popularity.
This study has some limitations: firstly, we did not have more individualized data for patients from each medical institution, such as tracheal intubation, central venous catheter, urine catheter, or surgery. Therefore, we did not include these factors in the study. Secondly, since our data comes from a big data platform, this database follows the principle of minimizing data and only collects the final results of the MIC values of pathogenic bacteria judged by various medical institutions’ microbiology laboratories according to CLSI standards. Therefore, we regret that we cannot obtain specific MIC values for more similar analysis. Thirdly, simple SMOTE technology cannot improve the predictive performance of the model, and more processing techniques need to be tried.
Data availability
The datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.
References
Fisher K, Phillips C (2009) The ecology, epidemiology and virulence of Enterococcus. Microbiology 155:1749–1757. https://doi.org/10.1099/mic.0.026385-0. (Reading)
García-Solache M, Rice LB (2019) The enterococcus: a model of adaptability to its environment. Clin Microbiol Rev 30(32):e00058-e118. https://doi.org/10.1128/CMR.00058-18
Carvalhaes CG, Sader HS, Flamm RK, Streit JM, Mendes RE (2020) Assessment of tedizolid in vitro activity and resistance mechanisms against a collection of Enterococcus spp. causing invasive infections, including isolates requiring an optimized dosing strategy for daptomycin from U.S. and European Medical Centers, 2016 to 2018. Antimicrob Agents Chemother 64:e00175-20. https://doi.org/10.1128/AAC.00175-20
Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ et al (2016) Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the national healthcare safety network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol 37:1288–1301. https://doi.org/10.1017/ice.2016.174
Weiner-Lastinger LM, Abner S, Edwards JR, Kallen AJ, Karlsson M, Magill SS et al (2020) Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network, 2015–2017. Infect Control Hosp Epidemiol 41:1–18. https://doi.org/10.1017/ice.2019.296
Lazaris A, Coleman DC, Kearns AM, Pichon B, Kinnevey PM, Earls MR et al (2017) Novel multiresistance cfr plasmids in linezolid-resistant methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium (VRE) from a hospital outbreak: co-location of cfr and optrA in VRE. J Antimicrob Chemother 1(72):3252–3257. https://doi.org/10.1093/jac/dkx292
Agyeman AA, Ofori-Asenso R (2016) Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob 22(15):41. https://doi.org/10.1186/s12941-016-0156-y
Wang Y, Lv Y, Cai J, Schwarz S, Cui L, Hu Z et al (2015) A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin. J Antimicrob Chemother 70:2182–2190. https://doi.org/10.1093/jac/dkv116
Deshpande LM, Ashcraft DS, Kahn HP, Pankey G, Jones RN, Farrell DJ et al (2015) Detection of a new cfr-like gene, cfr(B), in Enterococcus faecium isolates recovered from human specimens in the United States as Part of the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 59:6256–6261. https://doi.org/10.1128/AAC.01473-15
Candela T, Marvaud J-C, Nguyen TK, Lambert T (2017) A cfr-like gene cfr(C) conferring linezolid resistance is common in Clostridium difficile. Int J Antimicrob Agents 50:496–500. https://doi.org/10.1016/j.ijantimicag.2017.03.013
Antonelli A, D’Andrea MM, Brenciani A, Galeotti CL, Morroni G, Pollini S et al (2018) Characterization of poxtA, a novel phenicol-oxazolidinone-tetracycline resistance gene from an MRSA of clinical origin. J Antimicrob Chemother 1(73):1763–1769. https://doi.org/10.1093/jac/dky088
Sadowy E (2018) Linezolid resistance genes and genetic elements enhancing their dissemination in enterococci and streptococci. Plasmid 99:89–98. https://doi.org/10.1016/j.plasmid.2018.09.011
Yu L, Liu Y, Liu M, Li Z, Li L, Wang F (2022) Research note: molecular characterization of antimicrobial resistance and virulence gene analysis of Enterococcus faecalis in poultry in Tai’an, China. Poult Sci [Internet] [cited 2022 29];101. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904221/. https://doi.org/10.1016/j.psj.2022.101763
Samad MA, Sagor MS, Hossain MS, Karim MR, Mahmud MA, Sarker MS et al (2022) High prevalence of vancomycin non-susceptible and multi-drug resistant enterococci in farmed animals and fresh retail meats in Bangladesh. Vet Res Commun 26. https://doi.org/10.1007/s11259-022-09906-7
Chawla NV, Bowyer KW, Hall LO, Kegelmeyer WP (2002) SMOTE: synthetic minority over-sampling technique. J Artif Intell Res 1(16):321–357. https://doi.org/10.1613/jair.953
DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845
Hao W, Shan X, Li D, Schwarz S, Zhang S-M, Li X-S et al (2019) Analysis of a poxtA- and optrA-co-carrying conjugative multiresistance plasmid from Enterococcus faecalis. J Antimicrob Chemother 1(74):1771–1775. https://doi.org/10.1093/jac/dkz109
Shen J, Wang Y, Schwarz S (2013) Presence and dissemination of the multiresistance gene cfr in Gram-positive and Gram-negative bacteria. J Antimicrob Chemother 68:1697–1706. https://doi.org/10.1093/jac/dkt092
Souli M, Sakka V, Galani I, Antoniadou A, Galani L, Siafakas N et al (2009) Colonisation with vancomycin- and linezolid-resistant Enterococcus faecium in a university hospital: molecular epidemiology and risk factor analysis. Int J Antimicrob Agents 33:137–142. https://doi.org/10.1016/j.ijantimicag.2008.08.017
Pidot SJ, Gao W, Buultjens AH, Monk IR, Guerillot R, Carter GP et al (2018) Increasing tolerance of hospital Enterococcus faecium to handwash alcohols. Sci Transl Med 10:eaar6115. https://doi.org/10.1126/scitranslmed.aar6115
Namaki Kheljan M, Teymorpour R, Peeri Doghaheh H, Arzanlou M (2022) Antimicrobial biocides susceptibility and tolerance-associated genes in Enterococcus faecalis and Enterococcus faecium isolates collected from human and environmental sources. Curr Microbiol 27(79):170. https://doi.org/10.1007/s00284-022-02858-w
Olearo F, Both A, Belmar Campos C, Hilgarth H, Klupp E-M, Hansen JL et al (2021) Emergence of linezolid-resistance in vancomycin-resistant Enterococcus faecium ST117 associated with increased linezolid-consumption. Int J Med Microbiol 311:151477. https://doi.org/10.1016/j.ijmm.2021.151477
Bai B, Hu K, Zeng J, Yao W, Li D, Pu Z et al (2019) Linezolid consumption facilitates the development of linezolid resistance in Enterococcus faecalis in a tertiary-care hospital: a 5-year surveillance study. Microb Drug Resist 25:791–798. https://doi.org/10.1089/mdr.2018.0005
Smith TT, Tamma PD, Do TB, Dzintars KE, Zhao Y, Cosgrove SE et al (2018) Prolonged linezolid use is associated with the development of linezolid-resistant Enterococcus faecium. Diagn Microbiol Infect Dis 91:161–163. https://doi.org/10.1016/j.diagmicrobio.2018.01.027
Rodríguez-Noriega E, Hernández-Morfin N, Garza-Gonzalez E, Bocanegra-Ibarias P, Flores-Treviño S, Esparza-Ahumada S et al (2020) Risk factors and outcome associated with the acquisition of linezolid-resistant Enterococcus faecalis. J Glob Antimicrob Resist 21:405–409. https://doi.org/10.1016/j.jgar.2020.01.010
Vikesland P, Garner E, Gupta S, Kang S, Maile-Moskowitz A, Zhu N (2019) Differential drivers of antimicrobial resistance across the world. Acc Chem Res 16(52):916–924. https://doi.org/10.1021/acs.accounts.8b00643
Collignon P, Beggs JJ, Walsh TR, Gandra S, Laxminarayan R (2018) Anthropological and socioeconomic factors contributing to global antimicrobial resistance: a univariate and multivariable analysis. Lancet Planet Health 2:e398-405. https://doi.org/10.1016/S2542-5196(18)30186-4
Park K, Jeong YS, Chang J, Sung H, Kim MN (2020) Emergence of optrA-mediated linezolid-nonsusceptible Enterococcus faecalis in a tertiary care hospital. Ann Lab Med 40:321–325. https://doi.org/10.3343/alm.2020.40.4.321
Bender JK, Cattoir V, Hegstad K, Sadowy E, Coque TM, Westh H et al (2018) Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature. Drug Resist Updat 40:25–39. https://doi.org/10.1016/j.drup.2018.10.002
Kerschner H, Cabal A, Hartl R, Machherndl-Spandl S, Allerberger F, Ruppitsch W et al (2019) Hospital outbreak caused by linezolid resistant Enterococcus faecium in Upper Austria. Antimicrob Resist Infect Control 9(8):150. https://doi.org/10.1186/s13756-019-0598-z
Jung J, Park K, Shin S-H, Lee J-Y, Kim M-N, Kim S-H (2019) The pitfall of cohort isolation in an outbreak of linezolid-resistant, vancomycin-resistant enterococci. Clin Microbiol Infect 25:1568–1569. https://doi.org/10.1016/j.cmi.2019.08.014
Funding
This work was supported by the Natural Science Foundation of Fujian Province, China (Grant No. 2021J01756).
Author information
Authors and Affiliations
Contributions
All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by PL, BZ, XW, FZ, YZ, and XL. The first draft of the manuscript was written by PL and all authors commented on previous versions of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Below is the link to the electronic supplementary material.
10096_2023_4717_MOESM1_ESM.tif
Supplementary file1 (TIF 334 KB) Supplementary Figure A2 The calibration plot of the logistic regression and ANN prediction models. a: The calibration plot of the Logistic regression and ANN prediction models without SMOTE. b: The calibration plot of the Logistic regression and ANN prediction models with SMOTE.
10096_2023_4717_MOESM2_ESM.docx
‘Supplementary file2 (DOCX 21 KB) Supplementary Table A1 Basic characteristics of predictive factors related to E. faecalis.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Liu, P., Zeng, B., Wu, X. et al. Risk exploration and prediction model construction for linezolid-resistant Enterococcus faecalis based on big data in a province in southern China. Eur J Clin Microbiol Infect Dis 43, 259–268 (2024). https://doi.org/10.1007/s10096-023-04717-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-023-04717-3